RA Capital Nexus Fund, L.P.
SEC-identified person · CIK 1780117 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Artiva Biotherapeutics, Inc. ARTV | Director | filed 2024–2026 |
| Sionna Therapeutics, Inc. SION | Director | filed 2025–2026 |
| Nkarta, Inc. NKTX | Director | filed 2022–2026 |
| Eliem Therapeutics, Inc. ELYM | Director | filed 2021–2026 |
| Tyra Biosciences, Inc. TYRA | Director | filed 2021–2026 |
| 89bio, Inc. ETNB | Director | filed 2022–2025 |
| Vor Biopharma Inc. VOR | Director | filed 2024–2025 |
| Jade Biosciences, Inc. JBIO | Director | filed 2021–2024 |
| Solid Biosciences, LLC SLDB | Director | filed 2022–2024 |
| Black Diamond Therapeutics, Inc. BDTX | Director | filed 2023–2023 |
| Icosavax, Inc. ICVX | Director | filed 2023–2023 |
| Akouos, Inc. AKUS | Officer | filed 2020–2020 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.